Senior Management Appointment and Options Grant
e-therapeutics plc is pleased to announce the appointment of Alison Gallafent as Head of Intellectual Property for the Company, and a grant of options to certain members of the senior management.
Alison Gallafent is a UK Chartered Patent Attorney and European Patent Attorney, who brings considerable intellectual property expertise to e-therapeutics, with over 20 years of experience in the pharmaceutical and biotech industries.
Alison has previously worked as in-house Patent Counsel for a range of pharmaceutical companies, such as Merck and Co., Glaxo Wellcome, PLIVA and more recently as Head of IP at Silence Therapeutics plc. She has also held senior patent attorney roles in several leading international law firms and has successfully represented many international pharmaceutical companies in high profile and pivotal patent cases before the European Patent Office.
Alison also brings a wealth of knowledge of the siRNA patent landscape to the Company, and how to strategically operate in this field.
I am delighted to be joining the e-therapeutics team. I am very excited to be part of the process of creating meaningful Intellectual Property assets for the Company at this stage of its development, based on using the Company's computational biology drug discovery platform to develop clinically validated siRNA drugs.
Head of Intellectual Property
We are delighted to welcome Alison to e- therapeutics at this point in the Company's evolution. The combination of her broad industry and RNAi expertise will be a major addition to the team.
Chief Executive Officer
Grant of Options
As part of the Company's Long Term Incentive Plan, the Board has granted options over 500,000 and 1,250,000 ordinary shares of 0.1 pence each respectively to Alison Gallafent and Karl Keegan, Chief Financial Officer, who joined the Company in March 2021.
The options granted have an exercise price of £0.12, vest after three years and expire 10 years from the date of grant. Vesting or exercise of the options is not dependent on performance criteria.
Following this grant of options, the total number of ordinary shares under option is 25,772,836, representing 6.13 per cent. of the Company's issued share capital.